Results 31 to 40 of about 545,624 (314)
Simulation of the regulation of EGFR endocytosis and EGFR‐ERK signaling by endophilin‐mediated RhoA‐EGFR crosstalk [PDF]
FEBS Letters, 2008 Deregulations of EGFR endocytosis in EGFR‐ERK signaling are known to cause cancers and developmental disorders. Mutations that impaired c‐Cbl–EGFR association delay EGFR endocytosis and produce higher mitogenic signals in lung cancer. ROCK, an effector of small GTPase RhoA was shown to negatively regulate EGFR endocytosis via endophilin A1.
Ung, C.Y. +6 more
openaire +2 more sources
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
New England Journal of Medicine, 2016 BACKGROUND Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that is selective for both EGFR‐TKI sensitizing and T790M resistance mutations in patients with non–small‐cell lung cancer.
T. Mok +16 more
semanticscholar +1 more source
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR [PDF]
Oncogene, 2012 Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast
Li, X +7 more
openaire +2 more sources
Cancer Research, Statistics, and Treatment, 2019 Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra +5 more
doaj +1 more source
Медицинский совет, 2020 Introduction: Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates.
A. A. Lyanova +12 more
doaj +1 more source
Hittite Journal of Science and Engineering, 2023 Cancer, defined as the uncontrolled growth and proliferation of cells, is a serious disease seen in many people around the world. For this reason, a lot of work has been done and continues to be done by scientists for the diagnosis and treatment of ...
Serda Kecel Gunduz, Bilge Bıçak
doaj +1 more source
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas [PDF]
Clinical Cancer Research, 2021 Abstract Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomized clinical trials failed to show a
Simona Corso +41 more
openaire +4 more sources
Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
Molecules, 2020 Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer.
Yann-Lii Leu +6 more
doaj +1 more source
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
British Journal of Cancer, 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung ...
A. Leonetti +5 more
semanticscholar +1 more source
JTO Clinical and Research ReportsIntroduction: The treatment landscape for people diagnosed with EGFR-mutated (EGFR-m) NSCLC has rapidly evolved, yet there remains limited self-reported information about the lived experience.
Jill Feldman, MA +8 more
doaj +1 more source